LLY Eli Lilly and Company
Company Analysis
Latest News
🔴 LLY is trading 2.3% down today as investors reassess GLP-1 economics after Medicare's Wegovy pilot
LLY is trading 2.3% down at $1201.96 as investors reassess GLP-1 economics following Medicare’s new Wegovy obesity-drug pilot and broader weight-loss coverage...
Sandoz files for generic Mounjaro and Zepbound, challenging Lilly’s weight-loss lead
The U.S. Food and Drug Administration accepted two applications from Sandoz for generic versions of Eli Lilly’s GLP-1 drugs, Mounjaro and Zepbound. Both...
🟢 LLY extends move to 6.3% up
LLY is trading at $1199.00, up 6.3% versus the comparison close of $1127.69 during regular trading. This is a price-movement alert; no separate...
🟢 LLY up 4.1% today as Eli Lilly's Jaypirca receives positive EU recommendation for CLL
Eli Lilly (LLY) is trading 4.1% up at $1,173.96 today, following a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products...
Eli Lilly offers Zepbound for $50, targeting 20 million Medicare patients
Eli Lilly and Company will launch its Medicare GLP-1 Bridge program on July 1, 2026. Eligible Medicare Part D patients will pay $50 per month for Zepbound...
🟢 LLY is trading 2.2% up today after a $1.9B Abbisko deal and China obesity drug optimism
LLY is trading 2.2% up at $1141.61 following news of a potential $1.9 billion research collaboration with Abbisko Therapeutics. • The partnership is...
Lilly Inks $1.9B R&D Deal, Eyes Late 2026 China Launch for Oral Obesity Drug
Eli Lilly announced a research and development collaboration with Chinese drug developer Abbisko Therapeutics potentially worth up to $1.9 billion. [6, 8]...
Eli Lilly seals $7.8B Centessa acquisition, expanding sleep-wake disorder pipeline
Eli Lilly will finalize its acquisition of Centessa Pharmaceuticals on June 24, 2026. The High Court of Justice of England and Wales has granted final approval...
Eli Lilly Partners with BioArctic in $800M Deal for Neuro-Drug Technology
Eli Lilly entered a research and collaboration agreement with Swedish biopharma firm BioArctic. The partnership combines an undisclosed Lilly drug candidate...
Eli Lilly advances lepodisiran to Phase 3, targeting genetic heart disease risk
Eli Lilly has launched the ACCLAIM-Lp(a) Phase 3 clinical trial for its investigational drug, lepodisiran. The study evaluates the therapy's ability to reduce...
Eli Lilly's Strong Growth Fuels Analyst Predictions of $1,200 Stock Price
Analysts predict Eli Lilly's stock price could reach or exceed $1,200 per share. The company's exceptional financial performance and market dominance in...
🔴 Eli Lilly and Company is trading 2% down today as FDA sends warning letters over compounded weight-loss drugs
• Eli Lilly and Company is trading 2% down at $1089.60 today. • The U.S. Food and Drug Administration (FDA) issued warning letters to telehealth companies on...
Eli Lilly acquires 4E Therapeutics, expanding non-opioid pain relief pipeline
Eli Lilly and Co. acquired Austin-based neuroscience firm 4E Therapeutics for an undisclosed amount on June 16, 2026. The deal strengthens Lilly’s pipeline of...
Eli Lilly Jaypirca Combination Cuts Leukemia Progression Risk by 45%
Eli Lilly reported positive Phase 3 BRUIN CLL-322 trial results for its cancer drug Jaypirca (pirtobrutinib). Adding Jaypirca to a standard regimen of...
Eli Lilly Wins Court Order, Halting $200 Million Trulicity Rebate Fraud
Eli Lilly and Company secured a federal court order against pharmacy groups in Florida and Tennessee for an alleged $200 million fraud scheme. The network...
Eli Lilly and NVIDIA back Abridge to build medical AI operating system
Eli Lilly and NVIDIA are partnering with healthcare AI firm Abridge to develop a foundational AI model for medicine. The New York-announced collaboration aims...
Eli Lilly's Ebglyss Gets FDA Nod for Less Frequent Eight-Week Dosing
The U.S. Food and Drug Administration (FDA) approved a new maintenance dosing schedule for Eli Lilly's EBGLYSS (lebrikizumab-lbkz). This approval targets...
Eli Lilly enters vaccine market for $3.8B, diversifying beyond obesity drugs
Eli Lilly is entering the infectious disease market by acquiring three vaccine companies for a combined $3.83 billion. This strategic expansion diversifies a...
Eli Lilly strikes $1B AlzeCure deal, expanding Alzheimer’s pipeline
Eli Lilly and Company signed a global licensing agreement with Swedish biotech AlzeCure Pharma. The deal focuses on Alzstatin ACD680, a preclinical program for...
🟢 Eli Lilly and Company is trading 3.4% up today after positive late-stage obesity drug data
Eli Lilly and Company is trading 3.4% up at $1,170.00 after releasing highly positive late-stage clinical data for its next-generation obesity drugs presented...